NeuroSigma is commercializing external Trigeminal Nerve Stimulation (eTNS) technology for neurological and neuropsychiatric conditions. NeuroSigma’s lead product, the Monarch eTNS System for treating pediatric ADHD, is the first-ever medical device to receive FDA clearance for treating ADHD. This non-invasive, home-use bioelectronic therapy provides the efficacy of ADHD medications without the side effects. The Monarch is prescribed and dispensed like a medication and was recently issued two new Level II HCPCS codes by the Center for Medicare and Medicaid Services (CMS) to facilitate payer coding and coverage. NeuroSigma is currently seeking investors and strategic partnerships to facilitate commercialization of the Monarch eTNS System in the $10 billion U.S. ADHD market. In addition to ADHD, NeuroSigma has accumulated significant clinical data demonstrating that eTNS is an effective treatment for depression and epilepsy.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Monarch eTNS System
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):